These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36795508)

  • 41. Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.
    Feng X; Berklein F; Rane PB; Habib M; Lin PJ
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):965-973. PubMed ID: 32594283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. PCSK9 Inhibitors and Ezetimibe Monotherapy in Patients Not Receiving Statins: A Meta-Analysis of Randomized Trials.
    Benhuri B; Ueyama H; Takagi H; Briasoulis A; Kuno T
    Curr Vasc Pharmacol; 2021; 19(4):390-397. PubMed ID: 32767943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
    Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
    Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
    Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy.
    Warden BA; Minnier J; Watts GF; Fazio S; Shapiro MD
    J Clin Lipidol; 2019; 13(4):580-585. PubMed ID: 31130489
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model.
    Donald DR; Reynolds VW; Hall N; DeClercq J; Choi L
    J Clin Lipidol; 2022; 16(3):315-324. PubMed ID: 35367164
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Effect of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors on Circulating Endothelial Progenitor Cells in Patients with Cardiovascular Disease.
    Itzhaki Ben Zadok O; Mager A; Leshem-Lev D; Lev E; Kornowski R; Eisen A
    Cardiovasc Drugs Ther; 2022 Feb; 36(1):85-92. PubMed ID: 33394363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.
    Navar AM; Taylor B; Mulder H; Fievitz E; Monda KL; Fievitz A; Maya JF; López JAG; Peterson ED
    JAMA Cardiol; 2017 Nov; 2(11):1217-1225. PubMed ID: 28973087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice.
    Bradley CK; Kolkailah AA; Shah NP; Page CB; Peterson ED; Navar AM
    J Clin Lipidol; 2023; 17(3):412-414. PubMed ID: 37029056
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patient adherence to fully reimbursed proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) treatment.
    Stummer A; Ristl R; Kogler B; Muskovich M; Kossmeier M; Stulnig TM
    Wien Klin Wochenschr; 2023 Jul; 135(13-14):375-382. PubMed ID: 36808306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
    Koskinas KC; Gencer B; Nanchen D; Branca M; Carballo D; Klingenberg R; Blum MR; Carballo S; Muller O; Matter CM; Lüscher TF; Rodondi N; Heg D; Wilhelm M; Räber L; Mach F; Windecker S
    Eur J Prev Cardiol; 2021 Mar; 28(1):59-65. PubMed ID: 33755142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The First Report of a Real-world Experience With a PCSK9 Inhibitor in a Large Familial Hyperlipidemia and Very-high-risk Middle Eastern Population.
    Iqbal S; Sabbour HM; Siddiqui MS; Tikriti AA; Santos RD; Buckley A
    Clin Ther; 2022 Oct; 44(10):1297-1309. PubMed ID: 36127165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors.
    Leong D; Wu PE
    CMAJ; 2019 Aug; 191(32):E894. PubMed ID: 31405836
    [No Abstract]   [Full Text] [Related]  

  • 57. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing.
    Hess GP; Natarajan P; Faridi KF; Fievitz A; Valsdottir L; Yeh RW
    Circulation; 2017 Dec; 136(23):2210-2219. PubMed ID: 29084735
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world data on the prescription of proprotein convertase subtilisin/kexin type 9 inhibitors in high-risk patients in a tertiary medical center.
    Tsai CL; Chang YH; Su CH; Wu YJ; Yeh HI; Lin CF
    J Formos Med Assoc; 2022 Sep; 121(9):1877-1880. PubMed ID: 34852937
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Consensus statement of professional associations on prescribing of PCSK9-inhibitors].
    Češka R; Táborský M; Vrablík M
    Vnitr Lek; 2019; 64(12):1131-1136. PubMed ID: 30704246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
    Hagström E; Steg PG; Szarek M; Bhatt DL; Bittner VA; Danchin N; Diaz R; Goodman SG; Harrington RA; Jukema JW; Liberopoulos E; Marx N; McGinniss J; Manvelian G; Pordy R; Scemama M; White HD; Zeiher AM; Schwartz GG;
    Circulation; 2022 Aug; 146(9):657-672. PubMed ID: 35770629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.